Enzon Pharmaceuticals, Inc. (ENZN)

Enzon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	-	-	0.03	0.7	0.05	0.21
Revenue	-	-	0.03	0.7	0.05	0.21
Revenue Growth (YoY)	-	-	-96.29%	1248.08%	-74.88%	-97.01%
Gross Profit	-	-	0.03	0.7	0.05	0.21
Selling, General & Admin	1.09	1.04	1.06	1.17	1.36	1.18
Operating Expenses	1.09	1.04	1.06	1.17	1.36	1.18
Operating Income	-1.09	-1.04	-1.03	-0.47	-1.31	-0.97
Interest & Investment Income	2.46	2.26	0.65	0.01	-	-
Other Non Operating Income (Expenses)	-	-	-	-	0	-
EBT Excluding Unusual Items	1.38	1.22	-0.39	-0.46	-1.3	-0.97
Pretax Income	1.38	1.22	-0.39	-0.46	-1.3	-0.97
Income Tax Expense	-0.12	-0.16	-0.2	0.01	0.01	0.01
Net Income	1.5	1.37	-0.19	-0.47	-1.31	-0.98
Preferred Dividends & Other Adjustments	1.28	1.28	1.28	2.02	0.46	-
Net Income to Common	0.22	0.1	-1.46	-2.49	-1.77	-0.98
Net Income Growth	395.36%	-	-	-	-	-
Shares Outstanding (Basic)	74	74	74	74	51	44
Shares Outstanding (Diluted)	74	74	74	74	51	44
Shares Change (YoY)	-	-	-	45.23%	15.57%	-
EPS (Basic)	0.00	0.00	-0.02	-0.03	-0.03	-0.02
EPS (Diluted)	0.00	0.00	-0.02	-0.03	-0.03	-0.02
Free Cash Flow	1.39	1.31	-0.66	-0.5	-0.38	6.91
Free Cash Flow Per Share	0.02	0.02	-0.01	-0.01	-0.01	0.16
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-3969.23%	-66.90%	-2509.62%	-470.05%
Profit Margin	-	-	-	-66.90%	-	-
Free Cash Flow Margin	-	-	-2534.62%	-71.47%	-730.77%	3335.75%
EBIT	-1.09	-1.04	-1.03	-0.47	-1.31	-0.97
EBIT Margin	-	-	-	-66.90%	-	-
Revenue as Reported	-	-	0.03	0.7	0.05	0.21

Source: S&P Capital IQ. Standard template.